From GlobeNewswire: 2025-05-13 08:00:00

Ovid Therapeutics reports strong start in 2025 with promising pipeline progress and financial results. Topline results for OV329 Phase 1 study expected in Q3 2025, while OV350 Phase 1 safety data anticipated by year-end. Company’s cash position of $43.0 million as of March 31, 2025, to support operations through 2026. Clinical pipeline advancing with focus on neurological and neuropsychiatric conditions. Biomarker strategy for OV329 includes TMS, MRS, and QEEG measurements to assess potential clinical effect and target engagement. Phase 1 trial of OV350, a KCC2 direct activator, initiated in March 2025. Preclinical pipeline includes three KCC2 direct activator molecules advancing in IND-enabling studies. OV4071, an oral KCC2 direct activator, on track to start proof-of-concept study in H1 2026 for psychosis associated with NSD. Financially, Ovid reports revenue of $130,000 for Q1 2025, with net loss of $10.2 million. Company’s cash, cash equivalents, and marketable securities total $43.0 million as of March 31, 2025, with working capital of $36.6 million. Ovid’s business strategy includes exploring partnerships, co-development opportunities, and cost-saving efforts to support pipeline development and key milestones through 2026. Forward-looking statements indicate Ovid’s focus on clinical studies, potential therapeutic opportunities, and future business development.



Read more at GlobeNewswire:: Ovid Therapeutics Reports Business Updates and First